ECSP088411A - USE OF SDF-1 FOR THE TREATMENT AND / OR PREVENTION OF NEUROLOGICAL DISEASES. - Google Patents

USE OF SDF-1 FOR THE TREATMENT AND / OR PREVENTION OF NEUROLOGICAL DISEASES.

Info

Publication number
ECSP088411A
ECSP088411A EC2008008411A ECSP088411A ECSP088411A EC SP088411 A ECSP088411 A EC SP088411A EC 2008008411 A EC2008008411 A EC 2008008411A EC SP088411 A ECSP088411 A EC SP088411A EC SP088411 A ECSP088411 A EC SP088411A
Authority
EC
Ecuador
Prior art keywords
sdf
prevention
treatment
neurological diseases
neurological
Prior art date
Application number
EC2008008411A
Other languages
Spanish (es)
Inventor
Ursula Boschert
Amanda Proudfoot
Linda Kadi
Pierre Alain Vitte
Jerome Wojcik
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of ECSP088411A publication Critical patent/ECSP088411A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere al uso de SDF-1, o de un agonista de actividad de SDF-1, para el tratamiento y/o prevención de una enfermedad neurológica.The invention relates to the use of SDF-1, or an agonist of SDF-1 activity, for the treatment and / or prevention of a neurological disease.

EC2008008411A 2005-10-31 2008-04-29 USE OF SDF-1 FOR THE TREATMENT AND / OR PREVENTION OF NEUROLOGICAL DISEASES. ECSP088411A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05110206 2005-10-31
US73414205P 2005-11-07 2005-11-07

Publications (1)

Publication Number Publication Date
ECSP088411A true ECSP088411A (en) 2008-05-30

Family

ID=38006228

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008411A ECSP088411A (en) 2005-10-31 2008-04-29 USE OF SDF-1 FOR THE TREATMENT AND / OR PREVENTION OF NEUROLOGICAL DISEASES.

Country Status (2)

Country Link
EC (1) ECSP088411A (en)
IL (1) IL190842A0 (en)

Also Published As

Publication number Publication date
IL190842A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
CL2016002589A1 (en) Use of compound genz-112638 (eliglustat), glucosylceramide synthase inhibitor, in the treatment of gaucher disease and fabry disease (divisional application 201201348).
CR10730A (en) ANTI NOTCH3 AGONIST ANTIBODIES AND THEIR USE IN THE TREATMENT OF DISEASES RELATED TO THE NOTCH3 GENE
PA8637301A1 (en) DERIVATIVES OF AMINO-5, 5-DIFENYLIMIDAZOLONE FOR THE INHIBITION OF THE B-SECRETASE
CL2007002017A1 (en) COMPOUNDS DERIVED FROM [4,5 '] - BIPIRIMIDINIL-6,4'-DIAMINE; PHARMACEUTICAL COMPOSITION; AND USE AS AN INHIBITOR OF THE ACTIVITY OF CINASA IN CANCER DE VEJIGA, CANCER CERVICAL AND MIELOMA MULTIPLE.
CL2007003495A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED CONDENSED HETEROCICLES, INHIBITORS OF THE ACTIVITY OF THE AKT; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OR PREVENTION OF CANCER.
BRPI0518228A (en) mitotic kinesin inhibitors and methods of use of these
AR061446A1 (en) USE OF 1,7-DIMETHYLXANTINE FOR THE MANUFACTURE OF A NON-ANIOIOUS PSYCHOANALEPTIC DRUG FOR THE TREATMENT OF A NEUROPSYCHIATRIC DISORDER
AR059390A1 (en) USE OF FLIBANSERINE FOR THE TREATMENT OF PREMENOPAUSIC SEXUAL DESIRE DISORDERS
MX2007010560A (en) Roflumilast for the treatment of diabetes mellitus.
CL2007000595A1 (en) Piperidine derived compounds; Pharmaceutical composition and use for the treatment and / or prophylaxis of diseases selected from hypertension, congestive heart failure and renal failure, among others.
EA200702529A1 (en) FUNGICIDAL COMBINATION OF BIOLOGICALLY ACTIVE SUBSTANCES
WO2007013666A3 (en) Anti-tumor agents comprising r-spondins
UY28313A1 (en) NONADEPSIPEPTIDOS ACILADOS
AR058173A1 (en) USE OF SDF-1 FOR THE TREATMENT AND / OR PREVENTION OF NEUROLOGICAL DISEASES
AR057643A1 (en) LACOSAMIDE FOR ATTACHED THERAPY
EA200501528A1 (en) APPLICATION OF CLUSTERIN FOR THE TREATMENT AND / OR PREVENTION OF PERIPHERAL NEUROLOGICAL DISEASES
ITRM20050446A1 (en) USE OF HYDROXYLATED AND GLUCOSIDATED STYLBENES FOR THE PREVENTION AND TREATMENT OF EYE PATHOLOGIES.
HN2005030779A (en) NONADEPSIPEPTIDES ACILATED II
HN2003000104A (en) CYCLOPENTENE DERIVATIVES
DOP2006000024A (en) THIAZOLIDINONES, ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT
GT200600077A (en) IMIDAZOLS REPLACED WITH HETEROCICLILAMIDE
UY29417A1 (en) ENDOPARASITICID AGENTS
AR064214A1 (en) USE OF EPOTILONES IN THE TREATMENT OF OSTEOPOROSIS AND RELATED DISEASES
ECSP088411A (en) USE OF SDF-1 FOR THE TREATMENT AND / OR PREVENTION OF NEUROLOGICAL DISEASES.
DK1713438T3 (en) Medical soap